Skip to main content
Premium Trial:

Request an Annual Quote

Tripos Posts Strong Revenues, Growing Earnings for Q4 of 2004

NEW YORK, Feb. 22 (GenomeWeb News) - Tripos today reported a steep increase in revenues and earnings for the fourth quarter of 2004.

 

Revenues for the quarter totaled $17.3 million, up a third from $12.6 million during the same period a year ago. Most of the revenue growth during all of 2004 resulted from increases in discovery research products and services, the company said.

 

R&D costs decreased to $1.9 million, from $2.7 million during the fourth quarter of 2003.

 

Tripos had net earnings of $246,000, or $.03 per share for the quarter, an improvement over a net loss of $452,000, or $.05 per share, during the same quarter in 2003.

 

As of Dec. 31, Tripos had $4.2 million in cash and cash equivalents and $341,000 in marketable securities.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.